# A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

> **NCT00642538** · PHASE1 · COMPLETED · sponsor: **Mannkind Corporation** · enrollment: 20 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** MKC253 Inhalation Powder
- **DRUG:** Technosphere Inhalation Powder
- **DRUG:** subcutaneous injection

## Key facts

- **NCT ID:** NCT00642538
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2012-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00642538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00642538, "A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-09-10 from https://api.ai-analytics.org/clinical/NCT00642538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*